Pipeline

제넥신은 혁신적인 바이오 신약과 다양한 바이오베터를 개발하고 있습니다. 특히 희귀질병, 암 및 면역 질환 분야의 치료제 개발에 집중하고 있습니다.

HyTropin (long-acting hGH, GX-H9)

Indication Research Pre-Clinical Clinical Phase Site
I II III
성인 성장호르몬결핍증
 
 
EU/KR
소아 성장호르몬결핍증
 
 

HyPoietin (long-acting EPO, GX-E2)

Indication Research Pre-Clinical Clinical Phase Site
I II III
만성 신부전증에 의한 빈혈
 
 
KR

HyGrastim (long-acting G-CSF, GX-G3)

Indication Research Pre-Clinical Clinical Phase Site
I II III
호중구감소증
 
 
EU

HyGlutide (long-acting GLP-1, GX-G6)

Indication Research Pre-Clinical Clinical Phase Site
I II III
제2형 당뇨
 
 
EU

Papitrol-188 (HPV DNA Vaccine)

Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
자궁경부전암
단독투여
 
 
EU
자궁경부암 Pembrolizumab 병용투여
 
 
KR

Multi-Target Antibody Drug Candidates

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
Multi-Specific
(Bi-, Tri-)
 
 
KR

HyLeukin (IL-7-hyFc)

Areas Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
고형암 단독투여
 
 
KR
뇌암(교모세포종) 단독투여
 
 
KR
삼중음성 유방암 Pembrolizumab 병용투여
 
 
KR

HyLeukin (IL-7-hyFc), NIT와 공동개발

Areas Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
뇌암(교모세포종) 단독투여
 
 
US
병용투여(화학)
 
 
US
피부암(흑색종 등)
Atezolizumab 병용투여
 
 
US